Baxter Announces $100 Million Investment in BioPharma Solutions Halle/Westfalen, Germany Sterile Fill/Finish Manufacturing Facility
Baxter International Inc. (NYSE:BAX) has announced a significant investment of approximately $100 million to expand its sterile fill/finish manufacturing facility in Halle/Westfalen, Germany. This expansion will enhance production capabilities with a new syringe filling line and increased vial capacity, aimed at improving product stability and shelf life via lyophilization. The construction is set to start in 2022 and be completed by 2024, positioning Baxter to meet rising demand for injectable pharmaceuticals across Europe and the United States.
- Investment of approximately $100 million to expand manufacturing facility.
- Addition of state-of-the-art equipment to enhance product stability and shelf life.
- Construction of a new syringe filling line to meet growing demand.
- Facility recognized as a world-class manufacturer with over 60 years of experience.
- None.
Investment will add a syringe filling line, additional liquid and lyophilized (freeze dried) vial capacity and expand manufacturing footprint
This strategic investment will expand the BPS manufacturing footprint and add state-of-the-art equipment designed to help products achieve stability and improved shelf life through lyophilization (freeze drying). Construction will also add an aseptic syringe filling line, enabling BPS to meet the growing demand for this delivery platform in both
“Baxter’s manufacturing site in Halle/Westfalen is one of the most advanced facilities in our global network and has seen significant growth over the last several years,” said
Baxter’s Halle/Westfalen,
About Baxter's BioPharma Solutions Business
Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise, sterile manufacturing solutions, parenteral delivery systems and customized support services needed to meet the unique challenges that parenteral products face. For more information, please visit: biopharmasolutions.baxter.com.
About Baxter
Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products. For 90 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.
This release includes forward-looking statements concerning Baxter BioPharma Solutions, including the proposed investment in the expansion of its facilities. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: the company’s ability to finance the planned investment and to develop new products or enhancements; satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply, or patient safety issues; changes in law and regulations; and other risks identified in Baxter's most recent filing on Form 10-K and other
Baxter and BioPharma Solutions are registered trademarks of
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005730/en/
Media Contact
media@baxter.com
Investor Contact
Source:
FAQ
What is Baxter's planned investment in its manufacturing facility?
When is the construction of Baxter's new manufacturing facility expected to start?
What new capabilities will Baxter's expansion add?
How will the expansion impact Baxter's operations?